La Ro Cor s.r.o.
- Address
- Snp 26, 972 51 Handlova, Slovakia
La Ro Cor s.r.o. - Cardiovascular Research Center
La Ro Cor s.r.o. is a specialized medical research facility dedicated to advancing cardiovascular disease treatment through participation in cutting-edge clinical trials. The center focuses on investigating novel therapeutic interventions for complex cardiovascular conditions, with particular expertise in both preventive cardiology and advanced heart failure management.
- Lipoprotein(a) modulation and cardiovascular risk reduction in patients with established cardiovascular disease
- Heart failure with reduced ejection fraction (HFrEF) treatment optimization
- Novel pharmacological interventions targeting major adverse cardiovascular events (MACE)
The research center participates in multicenter Phase 2 and Phase 3 trials evaluating innovative compounds such as pelacarsen for lipid management and tovinontrine for chronic heart failure. Their clinical research portfolio emphasizes the assessment of therapies aimed at reducing cardiovascular mortality, myocardial infarction, stroke, and urgent coronary revascularization, while also investigating biomarker-driven approaches using NT-proBNP monitoring in heart failure populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Novartis Pharma AG1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in La Ro Cor s.r.o.
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Baxdrostat and Dapagliflozin on Heart Failure Incidence and Cardiovascular Mortality in High-Risk Patients: A Phase III Randomized Controlled Trial | AstraZeneca AB | Phase III | Recruiting | May 2025 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pelacarsen | 2 | Unknown | 2020-03-06 | 2026-05-11 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.